Cognition Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CGTX Nasdaq 8731 http://www.cogrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cognition Therapeutics Inc

Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease - Dec 22nd, 2022 1:00 pm
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023" - Dec 21st, 2022 9:05 pm
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812 - Dec 15th, 2022 1:00 pm
Cognition Therapeutics, Inc.'s (NASDAQ:CGTX) market cap surged US$46m last week, individual investors who have a lot riding on the company were rewarded - Dec 1st, 2022 1:38 pm
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD - Dec 1st, 2022 12:30 pm
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD - Nov 28th, 2022 1:00 pm
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series - Nov 21st, 2022 1:00 pm
Cognition Therapeutics Announces Closing of Public Offering - Nov 15th, 2022 5:55 pm
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 14th, 2022 1:00 pm
Cognition Therapeutics Announces Pricing of Public Offering - Nov 10th, 2022 1:00 pm
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S. - Oct 12th, 2022 12:00 pm
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development - Oct 11th, 2022 12:00 pm
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference - Sep 29th, 2022 11:30 am
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial - Sep 27th, 2022 11:32 am
Cognition Therapeutics Announces Participation in September Investment Conferences - Sep 6th, 2022 11:32 am
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth - Aug 11th, 2022 10:56 am
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 9th, 2022 11:00 am
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes - Aug 4th, 2022 8:02 pm
EXCLUSIVE: Cognition Therapeutics Shares Biomarker Data From Alzheimer's Candidate - Aug 4th, 2022 6:30 pm
Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 - Aug 3rd, 2022 8:05 pm